JOLTS Job Openings (Jun) 7.44M vs 7.5M Expected
In a recent transaction, Jon Bates, Chief Financial Officer of Nutex Health , Inc. (NASDAQ:NUTX), purchased 1,000 shares of the company’s common stock on April 8, 2025. The shares were acquired at a price of $81.81 each, amounting to a total investment of $81,810. The stock has since rallied significantly, trading at $129.67, representing a 58% gain on his investment. According to InvestingPro, the company has demonstrated remarkable momentum with a 75% return in the past week alone.
Additionally, Bates acquired 1,611 shares of common stock on March 1, 2025, through the conversion of restricted stock units (RSUs). These RSUs were converted at no cost, as they transform into common stock on a one-for-one basis. Furthermore, on March 10, 2025, Bates was granted 3,500 RSUs, which are set to vest in three equal installments over the next three years. The company, currently valued at $730 million, maintains strong financial health with a "GREAT" overall score from InvestingPro’s comprehensive analysis.
Following these transactions, Bates now owns a total of 6,500 shares of Nutex Health common stock. With the stock trading near its 52-week high of $134.53 and showing a remarkable 1,868% return over the past year, InvestingPro analysis suggests the stock is currently in overbought territory.
In other recent news, Nutex Health reported a significant surge in revenue for the fourth quarter of 2024, reaching $257.6 million, which marks a 270% increase from the same period last year. This impressive growth is largely attributed to the company’s successful arbitration processes, which contributed to 90.3% of the revenue increase. For the entire year, Nutex Health’s revenue climbed to $479.9 million, up 94% from 2023, while adjusted EBITDA for the full year rose by an extraordinary 1000%. The company also achieved a net income of $52.2 million, a major improvement from a net loss of $45.8 million in 2023.
Benchmark has raised its price target for Nutex Health shares to $150, up from the previous $60, maintaining a Buy rating. This adjustment follows Nutex Health’s robust fourth-quarter performance, driven by its strategic shift to arbitration under the No Surprise Act, which achieved over an 80% success rate with claims in 2024. Looking ahead, Nutex Health plans to open three new hospitals in late 2025, with an additional four hospitals expected in 2026, as part of its ongoing expansion efforts. The company is also focusing on increasing service diversity and implementing AI technologies to enhance operational efficiency and cost savings. Nutex Health’s strategic initiatives and strong financial results indicate a positive trajectory for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.